fda bans compounded semaglutide and tirzepatide Tirzepatide! Now What? Compounding pharmacies can resume making

Koehler JA, Baggio LL, Lamont BJ, Ali S, and Drucker DJ

How to Reduce the Risk Watch for symptoms

Obesity-related chronic inflammation contributes not only to the alteration of cardiac metabolism, but also to the accumulation of epicardial adipose tissue, which can aggravate the hemodynamic profile and worsen cardiac function

Risk factors that increased the likelihood of developing NAION included a history of DR, insulin use, male sex, white race, dual eligibility in Medicare and Medicaid, rural residency, sleep apnea and concurrent use of amiodarone and GLP-1 agonists

Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label